Physician profile
Michael E Welling
NPI 1821060294
$3,190.11
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,476 · 2020: $116 · 2022: $75.59 · 2023: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $753.33 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $627.00 | 2019-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $443.06 | 2019 | |
| Allergan, INC. | $196.24 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $139.66 | 2019 | |
| Tris Pharma INC | $138.12 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $122.78 | 2019 | |
| Corium, LLC | $117.86 | 2022-2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.22 | 2023 | |
| Abbvie INC. | $112.94 | 2023 | Vraylar |
| Alkermes, INC. | $103.86 | 2022-2023 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.96 | 2019 | |
| Bioxcel Therapeutics, INC. | $78.48 | 2023 | Igalmi |
| Supernus Pharmaceuticals, INC. | $19.68 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $15.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Welling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.